Skip to content
value.today

BioNumerik Pharmaceuticals, Inc.

Total raised
$11 M
2 rounds on record
Latest round
$10 M
Oct 2012
First round on record
Oct 2010
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of BioNumerik Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2012$10 MNo. 2$10 to $50 million

BioNumerik Pharmaceuticals, Inc.: Raise no. 2, Oct 2012

Investors in this round

3 investors had bought by the notice of Nov 8, 2012: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $29 M offered; $19 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$700,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Texas

People named in the notice

  • David R. Margrave · Executive Officer · Chief Administrative Officer, General Counsel, Vice President and Secretary
  • Frederick H. Hausheer · Executive Officer, Director · Chairman, Chief Executive Officer and President
  • Harry R. Kochat · Executive Officer · Vice President, Drug Process Development & Manufacturing
  • Stacey R. Bain · Executive Officer · Vice President of Clinical Product Development
  • Dennert O. Ware · Director
  • Harry R. Jacobson · Director
  • Homer L. Pearce · Director
  • James R. Leininger · Director
  • John W. Yarbro · Director
  • Steve W. Carchedi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount and Total Remaining to be Sold includes $6,875,846 potential proceeds from the exercise of warrants issued or to be issued as part of the transaction.”
  • On the use of proceeds: “Proceeds will be used to fund on-going financial requirements, including 2 on-going Phase III clinical trials for 2 different oncology drug candidates. A portion may be used for executive salaries in ordinary course, but no particular amt. is so budgeted.”

Signed by Frederick H. Hausheer, Chairman & CEO. Source: SEC Form D, newest notice filed Nov 8, 2012. Read the notice at the SEC.

equity, optionsSEC
Oct 2010$1 MNo. 1Under $2 million

BioNumerik Pharmaceuticals, Inc.: Raise no. 1, Oct 2010

Investors in this round

4 investors had bought by the notice of Nov 12, 2010: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $26 M offered; $25 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$650,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Texas

People named in the notice

  • David R. Margrave · Executive Officer · Chief Administrative Officer and General Counsel
  • Frederick H. Hausheer · Executive Officer, Director · Chairman and Chief Executive Officer
  • Harry R. Kochat · Executive Officer · Vice President, Drug Process Development & Manufacturing
  • Stacey R. Bain · Executive Officer · Vice President of Clinical Product Development
  • Dennert O. Ware · Director
  • Harry R. Jacobson · Director
  • James R. Leininger · Director
  • John W. Yarbro · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount and Total Remaining to be Sold includes $6,250,755 potential proceeds from the exercise of warrants issued as part of the transaction.”
  • On the use of proceeds: “Proceeds will be used to fund operations, including funding of two on-going Phase III clinical trials for two different oncology drug candidates. A portion may be used for executive salaries in ordinary course, but no particular amount is so budgeted.”

Signed by David R. Margrave, Chief Administrative Officer, General Counsel. Source: SEC Form D, newest notice filed Nov 12, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • BioNumerik Pharmaceuticals, Inc. had revenue of up to $1 million when it filed its newest notice of a funding round (Nov 2012).

    SEC Form D (revenue range) · Nov 2012

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2012

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of BioNumerik Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 4 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BioNumerik Pharmaceuticals, Inc.
NameRoleNamed in
David R. MargraveChief Administrative Officer, General Counsel, Vice President and SecretaryNov 2012
Frederick H. HausheerChairman, Chief Executive Officer and PresidentNov 2012
Harry R. KochatVice President, Drug Process Development & ManufacturingNov 2012
Stacey R. BainVice President of Clinical Product DevelopmentNov 2012
Dennert O. WareDirectorNov 2012
Frederick H. HausheerChairman, Chief Executive Officer and PresidentNov 2012
Harry R. JacobsonDirectorNov 2012
Homer L. PearceDirectorNov 2012
James R. LeiningerDirectorNov 2012
John W. YarbroDirectorNov 2012
Steve W. CarchediDirectorNov 2012